BiOrion Technologies

BiOrion is a clinical stage Dutch biopharmaceutical drug discovery company involved in developing targeted therapeutics and companion imaging diagnostics for myofibroblast-associated diseases, such as hepatic, renal, cardiac and idiopathic pulmonary fibrosis and fibrosis-associated cancers such as colorectal and pancreatic cancer. BiOrion's platform and drug development engine is based on proprietary PDGF-ß-receptor medium-affinity binding bicyclic peptides. PDGF is one of the main drivers of fibrosis, and its receptor is specifically over-expressed on myofibroblasts, the key pathogenic cells, whereas the expression on other cell types is rather low or even absent. The medium-affinity binding to the over-expressed receptor allows myofibroblast-specific targeting of diagnostic labels and (existing) antifibrotic drugs in fibrotic diseases. BiOrion is presently engaged in research collaborations with major pharmaceutical companies on its drug development programs.